JPRN-UMIN000014486已完成未知
Efficacy and security of certolizumab pegol treatment in patients with reumatoid arthritis - Saitama East Study
Saitama East Study Group0 个研究点目标入组 100 人开始时间: 2014年12月1日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients have other rheumatic diseases. 2. Patients have malignant disorders in recent 5 years. 3.Patients have a risk for tuberculosis. 4.Patients who develpoprd bacterial infection and antibiotics were administrated within 30 days after first CPZ treatment. 5.Drug or alcohol addiction or abusers. 6.Patients who are not able to be adequately evaluated in this study. 7.Patients who have Type B viral hepatitis. 8.Patients who have nontuberculous mycobacteril infection. 9.Patients who have congestive heart failure(>II).
研究者
相似试验
已完成
不适用
Efficacy and safety of certolizumab pegol in patients with rheumatoid arthritis who failed to respond to a single previous TNF inhibitorRheumatoid arthritisJPRN-UMIN000020154Saitama Medical University, Department of Rheumatology and Applied Immunology150
已完成
3 期
A Study to Evaluate the Pharmacokinetics, Safety, and Effectiveness of Certolizumab Pegol in Children With Moderate to Severe Chronic Plaque PsoriasisModerate Chronic Plaque PsoriasisSevere Chronic Plaque PsoriasisMixed Guttate/Plaque PsoriasisNCT04123795UCB Biopharma SRL49
已完成
2 期
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic PsoriasisModerate to Severe PsoriasisGeneralized Pustular Psoriasis and Erythrodermic PsoriasisNCT03051217UCB Biopharma S.P.R.L.127
招募中
不适用
Certolizumab Pegol treatment with Reducing and stoppIng MEthotrexate in patients with Rheumatoid Arthritis in stable low disease activity-stateRheumatoid arthritisJPRN-jRCTs041200048Asai Shuji88
进行中（未招募）
1 期
Prediction of response to Certolizumab Pegol treatment with MRI of the brain. A multi-center, randomized double-blind controlled studyPrediction of response to Certolizumab-Pegol in Rheumatoid Arthritis (PreCePRA)EUCTR2013-000337-13-PTniversitätsklinikum Erlangen156